Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.53 |
| ▸ | PPARA | Q07869 | 11/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855349 | 0.84 | PPARA (0.56) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5856042 | 0.82 | PPARG (0.51) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5858335 | 0.81 | PPARG (0.58) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5855653 | 0.80 | PPARG (0.48) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5857060 | 0.80 | PPARG (0.48) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5855420 | 0.75 | PPARG (0.56) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5856859 | 0.74 | PPARG (0.55) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5855804 | 0.73 | PPARG (0.53) | PPARGPPARASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5857590 | 0.72 | PPARG (0.55) | PPARGPPARAKDM4EPPARD | |
| SCHEMBL5857297 | 0.72 | PPARG (0.61) | PPARGPPARAKDM4EPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | PPARG 393/4885PPARA 464/4885SMN1; SMN2 4207/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | PPARG 603/4885PPARA 579/4885SMN1; SMN2 4287/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARG 701/4885PPARA 660/4885SMN1; SMN2 4370/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARG 701/4885PPARA 660/4885SMN1; SMN2 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.